Cullinan Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CGEM Nasdaq 2834 cullinantherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cullinan Therapeutics, Inc.

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 - Nov 14th, 2024 3:01 pm
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - Nov 7th, 2024 12:00 pm
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference - Nov 5th, 2024 12:00 pm
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 - Nov 4th, 2024 12:00 pm
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus - Oct 16th, 2024 11:00 am
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus - Sep 17th, 2024 11:00 am
Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus - Sep 16th, 2024 11:00 am
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024 - Sep 14th, 2024 8:15 am
Cullinan Therapeutics to Participate in Upcoming Investor Conferences - Aug 28th, 2024 12:00 pm
We Think Cullinan Therapeutics (NASDAQ:CGEM) Can Afford To Drive Business Growth - Aug 24th, 2024 1:28 pm
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results - Aug 8th, 2024 11:00 am
Institutional owners may ignore Cullinan Therapeutics, Inc.'s (NASDAQ:CGEM) recent US$92m market cap decline as longer-term profits stay in the green - Jun 4th, 2024 12:52 pm
Cullinan Therapeutics announces success for zipalertinib as combo therapy - Jun 3rd, 2024 10:26 am
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib - Jun 1st, 2024 11:00 am
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit - May 24th, 2024 12:00 pm
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024 - May 23rd, 2024 9:04 pm
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results - May 15th, 2024 8:05 pm
Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ... - May 9th, 2024 7:09 am
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer - Apr 29th, 2024 11:00 am
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? - Apr 24th, 2024 8:29 pm